"Specifically when we stratified by tertiles, we saw that at 15 years there was a significant difference in cancer-specific survival for those who had a high MMAI score vs lower MMAI scores," says Eric Li, MD.
In this video, Eric Li, MD, discusses the background and notable findings of the study “A.I. Derived Digital Pathology Biomarker Predicts Prostate Cancer Specific Survival for Patients Undergoing Radical Prostatectomy from PLCO Trial with Over 15 Years of Follow-Up,” presented at the 2023 Society of Urologic Oncology Annual Meeting. Li is a urology resident at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
We collaborated with ArteraAI, who previously developed this multimodal AI algorithm in patients mainly undergoing radiation. And so they collaborated with NRG Oncology and developed and validated this model previously in patients undergoing radiation. However, it hasn't really been looked at in patients undergoing surgery. So that was really the inspiration for our project here; to basically identify people from the PLCO cohort who underwent surgery and had digitized radical prostatectomy slides to see where this algorithm could be applied to them as well.
PLCO was originally a PSA screening trial started in the US in the 1990s. We identified a cohort of just over 1000 patients who had available digitized radical prostatectomy slides, as well as had relevant follow-up data. Our median follow-up was 17 years. Basically, we did a Cox model to look at factors associated with both prostate cancer-specific mortality as well as overall survival. And we also did a Kaplan Meier survival curve analysis.
First of all, we always think about patient selection. And so because it was a PSA screening trial, many of our patients had low-risk disease; actually, 90% of patients had NCCN low- or intermediate-risk prostate cancer at diagnosis. And we found that the MMAI models were predictive of both prostate cancer-specific mortality, as well as overall survival. And specifically when we stratified by tertiles, we saw that at 15 years there was a significant difference in cancer-specific survival for those who had a high MMAI score vs lower MMAI scores.
This transcription was edited for clarity.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).